NCT06383780 is a Phase 3 clinical trial of GP combined with Tislelizumab in Nasopharyngeal Carcinoma, sponsored by XIANG YANQUN.

Who is sponsoring NCT06383780?

NCT06383780 is sponsored by XIANG YANQUN.

What drugs are being tested in NCT06383780?

Interventions in NCT06383780: GP combined with Tislelizumab, TPC combined with Tislelizumab.

What condition does NCT06383780 study?

NCT06383780 studies Nasopharyngeal Carcinoma.

Is NCT06383780 still recruiting?

NCT06383780 is currently recruiting now. Last updated 16 July 2024.

Last reviewed 2024-07-16 · How we verify

NCT06383780

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Recruiting now Phase 3 Last updated 16 July 2024

What this trial tests

Phase 3 trial testing GP combined with Tislelizumab in Nasopharyngeal Carcinoma in 90 participants. Currently enrolling.

Timeline

15 May 2024

Primary endpoint
15 May 2027

15 May 2029

Quick facts

Lead sponsor	XIANG YANQUN
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	15 May 2024
Primary completion	15 May 2027
Estimated completion	15 May 2029
Sites	1 location across China

Drugs / interventions tested

GP combined with Tislelizumab — full drug profile →
TPC combined with Tislelizumab — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

XIANG YANQUN — full company profile →

Who can join

18 and older, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.
Spreafico A, Winquist E, Ho C, O'Sullivan B, et al · · 2025 · PMID 39851964 · DOI 10.3390/curroncol32010048

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other XIANG YANQUN trials

Trials by the same sponsor.

NCT06438627 — Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 T · Phase 3 · recruiting
NCT06414577 — Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Af · Phase 2 · active not recruiting
NCT05869227 — Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carc · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06383780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by XIANG YANQUN
Last refreshed: 16 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06383780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing